Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.
Int J Oncol
; 13(1): 57-63, 1998 Jul.
Article
in En
| MEDLINE
| ID: mdl-9625803
ABSTRACT
Primary therapy of advanced ovarian cancer is standardized, the therapy in relapsed ovarian cancer however is still controversial. In a prospective study the benefit of secondary surgery and/or second-line chemotherapy were evaluated. 139 patients with relapsed ovarian cancer were stratified according to a treatment plan patients with early relapse (recurrence-free interval 12 months) or primary progression during chemotherapy (n=43) were treated chemotherapeutically with etoposide (p.o. vs. i.v.). Patients with late relapse (recurrence-free interval >12 months, n=96) were referred, if possible, to a secondary debulking operation, followed by a platinum-based chemotherapy. Remission-rate, toxicity and survival time were analyzed. Median survival time in the
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Etoposide
/
Antineoplastic Agents, Phytogenic
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Int J Oncol
Journal subject:
NEOPLASIAS
Year:
1998
Type:
Article
Affiliation country:
Germany